All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Baseline characteristics predicting very good outcome of allogeneic hematopoietic cell transplantation in young patients with high cytogenetic risk chronic lymphocytic leukemia: a retrospective analysis from the chronic malignancies working party of the EBMT

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F17%3A00011777" target="_blank" >RIV/00023736:_____/17:00011777 - isvavai.cz</a>

  • Alternative codes found

    RIV/00669806:_____/17:10366038

  • Result on the web

    <a href="http://dx.doi.org/10.1016/j.clml.2017.06.007" target="_blank" >http://dx.doi.org/10.1016/j.clml.2017.06.007</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/j.clml.2017.06.007" target="_blank" >10.1016/j.clml.2017.06.007</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Baseline characteristics predicting very good outcome of allogeneic hematopoietic cell transplantation in young patients with high cytogenetic risk chronic lymphocytic leukemia: a retrospective analysis from the chronic malignancies working party of the EBMT

  • Original language description

    Patients with genetically high-risk relapsed/refractory chronic lymphocytic leukemia have shorter median progression-free survival (PFS) with kinase- and BCL2-inhibitors (KI, BCL2i). Allogeneic hematopoietic stem cell transplantation (alloHCT) may result in sustained PFS, especially in younger patients because of its age-dependent non-relapse mortality (NRM) risk, but outcome data are lacking for this population. Low predicted NRM and high 8-year PFS in favorable transplant high cytogenetic risk patients compares favorably with outcomes with KI or BCL2i. Taking into account the amount of uncertainty for predicting survival after alloHCT and after sequential administration of KI and BCL2i, alloHCT remains a valid option for younger patients with high cytogenetic risk chronic lymphocytic leukemia with a well-HLA-matched donor.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30205 - Hematology

Result continuities

  • Project

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2017

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Clinical lymphoma, myeloma & leukemia

  • ISSN

    2152-2650

  • e-ISSN

  • Volume of the periodical

    17

  • Issue of the periodical within the volume

    10

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    11

  • Pages from-to

    "667"-"675.e2"

  • UT code for WoS article

    000415142700008

  • EID of the result in the Scopus database

    2-s2.0-85021744361